MyFinsight
Home
Blog
About
Dare Bioscience, Inc. (DARE)
Dare Bioscience, Inc. (DARE)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$6,855,632
Unit: Dollar
Positive Cash Flow Breakdown
Net proceeds from issuance of se...
Depreciation and amortization
Write-off of deferred offering c...
Others
Negative Cash Flow Breakdown
Deferred grant funding
Prepaid expenses
Principal payments on financing ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-2,982,773
-2,999,889
-1,441,718
-3,562,766
Depreciation and amortization
572,143
554,643
534,395
481,906
Deferred financing cost amortization
-
-
-
124,251
Write-off of deferred offering costs
268,826
-
-
-
Right-of-use assets - operating lease
-131,659
-128,324
-134,646
-130,958
Stock-based compensation expense
286,602
455,064
357,160
403,027
Loss on disposal of property and equipment
-
-
0
0
Non-cash royalty revenue related to sale of future royalties
3,138
2,708
-10,755
202
Non-cash interest expense
14,808
14,809
-105,191
62,306
Accounts receivable
-123,827
120,633
12,053
-
Other receivables
-107,501
-5,938
191,851
181,041
Prepaid expenses
1,005,880
378,471
-114,230
-84,506
Deposits
-
0
0
-
Other current assets
322,016
194,717
12,246
53,159
Other non-current assets
314,541
1,436,824
35,071
72,722
Operating lease liabilities
-148,444
-145,108
-143,406
-138,894
Accounts payable
-392,990
-44,782
-621,272
518,208
Accrued expenses
-80,380
-13,338
-1,244,389
-618,168
Interest payable
165,485
158,042
154,554
149,269
Deferred grant funding
3,195,735
1,500,994
-5,094,190
-2,230,386
Deferred revenue
-
-
-1,000,000
-
Net cash used in operating activities
-6,775,046
-5,520,644
1,444,264
-442,135
Purchases of property and equipment
80,586
0
206,641
174,702
Net cash used in investing activities
-80,586
0
-206,641
-174,702
Net proceeds from issuance of common stock
166,700
94,887
20,930,126
-
Net proceeds from issuance of series a convertible preferred stock and warrants in connection with regulation a financing
1,232,695
297,213
-
-
Net proceeds from issuance of common stock
-
-
-
18,744,042
Payments of deferred offering costs
0
28,500
321,686
-
Repayment of liability on sale of future royalties
-
0
0
0
Issuance of note payable
-
-
1
486,720
Payments on note payable
0
182,521
182,521
121,680
Principal payments on financing lease
448,178
896,549
346,488
458,850
Net cash provided by financing activities
951,217
-715,470
424,129
18,650,232
Effect of exchange rate changes on cash and cash equivalents and restricted cash
2,225
44,542
-25,657
6,860
Net change in cash, cash equivalents and restricted cash
-5,902,190
-6,191,572
1,636,095
18,040,255
Cash, cash equivalents and restricted cash, beginning of period
18,819,784
25,011,356
23,375,261
15,998,174
Cash, cash equivalents and restricted cash, end of period
12,917,594
-
-
-
Cash and cash equivalents
12,617,594
-
-
-
Restricted cash included in other non-current assets
300,000
-
-
-
Total cash, cash equivalents and restricted cash
12,917,594
18,819,784
25,011,356
23,375,261
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net proceeds from
issuance of series a...
$1,232,695
Net proceeds from
issuance of common stock
$166,700
(-81.71%↓ Y/Y)
Net cash provided by
financing activities
$951,217
(369.08%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
$2,225
(-91.44%↓ Y/Y)
Canceled cashflow
$448,178
Net change in cash,
cash equivalents and...
-$5,902,190
(44.65%↑ Y/Y)
Canceled cashflow
$953,442
Depreciation and
amortization
$572,143
(-7.45%↓ Y/Y)
Stock-based compensation
expense
$286,602
(-61.08%↓ Y/Y)
Write-off of deferred
offering costs
$268,826
Interest payable
$165,485
(-38.42%↓ Y/Y)
Right-of-use assets -
operating lease
-$131,659
(47.61%↑ Y/Y)
Accounts receivable
-$123,827
Other receivables
-$107,501
(-156.77%↓ Y/Y)
Non-cash interest
expense
$14,808
(-88.19%↓ Y/Y)
Principal payments on
financing lease
$448,178
(-2.33%↓ Y/Y)
Net cash used in
operating activities
-$6,775,046
(37.78%↑ Y/Y)
Canceled cashflow
$1,670,851
Net cash used in
investing activities
-$80,586
(-1947.93%↓ Y/Y)
Deferred grant funding
$3,195,735
(-24.54%↓ Y/Y)
Net loss
-$2,982,773
(64.47%↑ Y/Y)
Prepaid expenses
$1,005,880
(314.13%↑ Y/Y)
Accounts payable
-$392,990
(-158.41%↓ Y/Y)
Other current assets
$322,016
Other non-current
assets
$314,541
(1182.01%↑ Y/Y)
Operating lease
liabilities
-$148,444
(44.26%↑ Y/Y)
Accrued expenses
-$80,380
(79.29%↑ Y/Y)
Non-cash royalty revenue
related to sale of future...
$3,138
(-26.25%↓ Y/Y)
Purchases of property and
equipment
$80,586
(1947.93%↑ Y/Y)
Buy us a coffee